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Abstract: This article examines the role of pegvisomant in the treatment of acromegaly. 
This syndrome, caused by excessive growth hormone (GH) secretion by a pituitary adenoma, 
is associated with a doubled mortality rate and poor quality of life. Pituitary microsurgery 
has long been the ﬁ  rst choice of treatment since it cures many patients, especially those with 
localized tumors. Adjuvant irradiation was given if insulin-like growth factor-I (IGF-I) or 
GH did not normalize. The introduction of long-acting slow- release somatostatin analogs 
was a breakthrough for adjuvant treatment, although not always effective. Rather, target-
ing excessive GH production, muting the GH signal at its receptor, was a totally different 
approach. The development of GH antagonists (by mutation of glycine at position 120) and 
other modiﬁ  cations to enhance receptor binding, and subsequent pegylation of the molecule 
led to the development of B2036. After pegylation of B2036 at 5 positions the distribution 
volume is restricted and its serum half-life considerably increased. In short-term clinical 
studies performed in selected, mostly pretreated, acromegalic patients, IGF-I normalized 
in the majority of cases. Combination therapy with long-acting somatostatin analogs and 
weekly rather than daily pegvisomant injections appears to be successful in one clinical 
study and might limit the high cost of pegvisomant. Long-term efﬁ  cacy and safety has to 
be demonstrated. The drug does not cross the blood–brain barrier, and whether it distributes 
freely into the extracellular space of other organs than the liver has not been investigated, 
which might have implications for persistent local IGF-I production under unrestrained GH 
concentrations.
Keywords: pegvisomant, Somavert, receptor antagonist, growth hormone, insulin-like growth 
factor-I, treatment
Introduction
The most obvious effect of growth hormone (GH) is promoting height in prepubertal 
and pubertal subjects by stimulating cell division and differentiation of chondroblasts 
in the growth plates of bones. In adult life, however, many other effects can be attrib-
uted to GH. These actions include stimulation of protein synthesis, increased lipolysis 
and inhibition of protein catabolism. GH is also involved in bone remodeling, muscle 
growth, insulin antagonism, renal sodium retention, and immuno-modulation. Most 
of these mentioned effects, however, are not the result of the direct action of GH, but 
they are mediated via insulin-like growth factor-I (IGF-I), a peptide synthesized and 
secreted after GH-signaling, which acts locally in a paracrine or autocrine fashion or 
distantly as a hormone, when secreted by the liver (Le Roith et al 2001). The latter 
organ is responsible for 70%–80% of the circulating IGF-I (Sjogren et al 1999; Sjogren 
et al 2002). The importance of IGF-I for body growth is underscored by observations 
of severely stunted growth in animals and the human with inactivating mutations IGF-I 
or its receptor (Woods et al 1996; Walenkamp et al 2005). Acquired GH deﬁ  ciency in 
the human leads to a characteristic syndrome, which can be treated successfully with International Journal of Nanomedicine 2006:1(4) 386
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physiological replacement therapy (Janssen et al 1997). In 
contrast, chronic excessive secretion of GH by a pituitary 
adenoma leads to acromegaly, a disﬁ  guring and debilitating 
condition, causing premature death (Ezzat et al 1994).
The purpose of this review is to discuss the role of the 
nanomedicine, pegvisomant in the treatment of acromegaly. 
Before discussing its role, we shall ﬁ  rst review brieﬂ  y 
essential aspects of GH physiology, GH molecular struc-
ture and signaling, the acromegaly syndrome and the cur-
rently used therapeutical approaches in the treatment of 
this disease.
Growth hormone physiology
Growth hormone is a single chain polypeptide hormone that 
is synthesized, stored and secreted by the somatotropic cells 
of the pituitary gland. The 22 kDa GH isoform represents 
90% of plasma GH (Baumann 1991). The other circulating 
GH molecule is the 20 kDa isoform, which is a post-transla-
tional RNA splicing variant form. In plasma, GH is mainly 
bound to the GH-binding protein (GHBP), which is derived 
from the extracellular domain of the GH receptor by proteo-
lytic cleavage (Sotiropoulos et al 1993). This binding protein 
may enhance or limit tissue actions of GH and reduces the 
GH clearance rate from 2–5 minutes (free GH) to 16–19 
minutes (bound GH). Growth hormone is cleared via renal 
and hepatic mechanisms.
Control of GH secretion is regulated at the hypothalamic 
and the pituitary level by stimulatory and inhibitory hormones 
resulting in a diurnal pulsatile secretion pattern by which the 
majority of GH is released during sleep (Giustina and Veldhuis 
1998). The hypothalamic stimulatory growth hormone-releas-
ing hormone (GHRH) stimulates GH gene transcription, 
GH-cell proliferation, and GH release. The hypothalamic 
inhibitory hormone somatostatin acts via binding of the 
somatostatin receptors and inhibits GH release from the secre-
tory granules in the somatotropes, but also attenuates GHRH 
release as illustrated in Figure 1. Other negative feedback sig-
nals regulating GH secretion are GH itself at the hypothalamic 
level and IGF-I at the hypothalamic and pituitary level. The 
physiological role of the GH-stimulatory hormone ghrelin, 
the native substrate for the GH- releasing peptide (GHRP) 
receptor, is not fully elucidated, but large GH responses are 
induced by GHRP or ghrelin infusion and this hormone acts 
synergistically with GHRH (Kojima et al 1999).
GH stimulates the production of IGF-I in many organs. 
IGF-I is a polypeptide belonging to the same family of growth 
factors as insulin. Most circulating IGF-I is bound to one of 
the six IGF binding proteins (IGFBPs), mainly to IGF-BP3 in 
a ternary complex with acid labile subunit (ALS). The serum 
IGF-I concentration reﬂ  ects the 24-hour GH secretion and 
is increased or decreased, when GH production is elevated 
or decreased, respectively. An important determinant for the 
IGF-I concentration is age. Increasing age is associated with 
a decreasing GH production and IGF-I concentration. Sex 
steroids, especially estrogens, inhibit GH-mediated IGF-I 
production. Malnutrition and anorexia nervosa are associated 
with high GH levels, but with low serum IGF-I concentra-
tions. On the other hand, obesity, especially visceral obesity 
is associated with a low serum GH concentrations, but with 
a normal serum IGF-I concentration (Giustina and Veldhuis 
1998; Pijl et al 2001).
Acromegaly
Acromegaly is a rare pituitary disorder, in which a pituitary 
adenoma hyper secretes GH. The incidence of acromegaly is 
3–4 per one million per year and the prevalence is 60–70 per 
one million as was found in the UK, Spain, and Sweden, 
without geographical and sex differences (Alexander et al 
1980; Bengtsson et al 1988; Ritchie et al 1990; Mestron 
et al 2004). The disease is likely under-diagnosed and it is 
possible that incidence and prevalence rates are therefore 
higher than previously reported. Acromegaly is associated 
with increased incidence of vascular disease, cardiomy-
opathy, and an increased prevalence of cardiac valvular 
abnormalities and malignancies, especially of the gastroin-
testinal tract (Colao 2004). Patients with active acromegaly 
GHRP’s
GH
GHRH Somatostatin
Figure 1 Schematic outline of the principal components of GH regulation, ie, 
somatostatin, GHRH, GHRPs (including ghrelin) and IGF-I. Circulating IGF-I is 
derived mainly from the liver and from other organs to a lesser extend. Positive 
stimulation and feedback are indicated by the + symbol, and inhibition or negative 
feedback by the – symbol.
Abbreviations: GHRH, hypothalamic stimulatory growth hormone-releasing 
hormone; GHRPs, GH- releasing peptides; IGF-1, insulin-like growth factor-I.International Journal of Nanomedicine 2006:1(4) 387
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have a two- to three-fold increased mortality risk due to 
cardiovascular and respiratory diseases and possibly cancer 
(Wright et al 1970).
Assessment of body composition in active acromegaly 
shows increased body weight and height, increased total 
body water and extracellular water, and reduced body fat 
(Bengtsson et al 1989). Due to hyperprolactinemia patients 
may have galactorrhea, amenorrhea, hirsutism, impotence, 
or infertility. Local tumoral effects include headache, visual 
ﬁ  eld defects with typical hemianopsia, and sporadically 
cerebral nerve dysfunction, especially of the trigeminal, 
trochlear, or abducens nerves. Hypopituitarism may occur in 
a small percentage of patients (∼10%) especially those with 
large tumors leading to symptoms related to hypothyroidism, 
hypogonadism and hypocortisolism.
Detailed studies of GH secretion in acromegaly have 
demonstrated increased basal GH production, increased 
pulse frequency, disturbed diurnal secretion and decreased 
regularity (Figure 2) (Ho and Weisberger 1994; van den 
Berg et al 1994).
Biochemical criteria for diagnosis and remission largely 
depend on the GH assay used. Therefore, reference values 
should be determined in each laboratory for all biochemical 
parameters used in the diagnosis and follow-up of patients 
with acromegaly. In healthy controls, after oral glucose 
load of 75 g the serum GH is suppressed to low levels. In 
contrast, in active acromegaly, the serum GH concentration 
is insufﬁ  ciently suppressed after glucose loading. The glu-
cose tolerance test (GTT) therefore provides a reproducible 
standardized test, although there are interpretative difﬁ  culties 
in overt diabetes mellitus and renal and hepatic disease. In 
addition, the test has not been validated for evaluation of the 
GH suppression during medical therapy (Giustina et al 2000; 
Freda 2003). No data are available on the relation between 
glucose-suppressed GH concentrations and morbidity and 
mortality.
Serum IGF-I, a marker that reﬂ  ects the mean serum 
GH concentration, is elevated in all patients with active 
acromegaly and may be decreased in the GH-deﬁ  cient state 
(Hoffman et al 1994; van der Lely et al 1997). As IGF-I 
concentration decreases with age, values should be interpreted 
after adjustment for age. In addition, gender, sex hormone 
status and body mass index may inﬂ  uence the serum IGF-I 
(and GH) concentrations. Importantly, normalized IGF-I 
after pituitary surgery leads to normal survival (Swaeringen 
et al 1998; Biermasz et al 2004).
Treatment of acromegaly
Treatment options in acromegaly are surgery, radiotherapy, 
and medical therapy or combinations of these and the various 
modalities are reviewed below.
Surgery
In most centers pituitary surgery is performed via the 
trans-sphenoidal route with very low mortality and low 
morbidity, although transcranial surgery may be required in 
very large suprasellar tumors. After selective and complete 
adenoma removal, GH secretion is reported to normalize 
completely (van den Berg et al 1998). Microadenoma (ie, 
adenoma smaller than 10mm) removal is successful in most 
cases (80%–90%), but with increasing size and expansion of 
the adenoma total tumor removal is more difﬁ  cult and only 
30%–40% of the patients with a large macroadenoma can 
be cured (Freda et al 1998; Biermasz et al 2000c). Second 
surgical procedures are generally safe, but less successful 
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Figure 2 Serum GH concentrations obtained by 10 min blood sampling for 24 
hours in a female patient with acromegaly and an age- and gender-matched healthy 
control subject. Note the difference in y-scale. In the patient, GH secretion is char-
acterized by the increased non-pulsatile component, increased pulsatile secretion, 
and burst frequency.
Abbreviation: GH, growth hormone.International Journal of Nanomedicine 2006:1(4) 388
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than primary surgery (Long et al 1996). The experience 
of the neurosurgeon is crucial for the success rate (Ahmed 
et al 1999).
Radiotherapy
Conventional radiotherapy is administered by a linear accel-
erator (4–8 MeV) in a total dose of 40–50 Gy fractionated 
in at least 20 sessions. A rotational ﬁ  eld, laterally opposed 
ﬁ  elds,or 3 ﬁ  elds have been used. A decline of about 50% 
in serum GH levels is observed in the ﬁ  rst 2 years after 
radiotherapy and after 5 years a 75% decline (Biermasz 
et al 2000a, 2000b; Wass 2003). Whether GH and IGF-I 
levels normalize in the follow-up mainly depends on the 
pre-irradiation serum GH concentration. Remission rates 
of radiotherapy are thus affected by surgical intervention 
(debulking) prior to radiotherapy. The incidence of hypo-
pituitarism increases with the duration after radiotherapy 
and about 50% of the patients require replacement therapy 
following radiotherapy (Biermasz et al 2000b).
Other radiation techniques include proton beam 
irradiation and stereotactic radiosurgery (gamma knife) 
(Mahmoud-Ahmed et al 2001). With radiosurgery a high 
single dose is administered at the stereotactically mapped 
region so that the tumor is ablated precisely while the 
surrounding tissue receives a low radiation dose. At present 
there is no convincing evidence available that radiosurgery is 
superior to conventional radiotherapy in terms of GH control, 
time needed for reaching safe GH levels, and incidence of 
hypopituitarism (Landolt et al 1998; Attanasio et al 2003; 
Biermasz et al 2006).
Medical treatment
Medical therapy for acromegaly started with the use of 
estrogens and later with chlorpromazine, but the important 
break-through came with the discovery that dopamine and 
bromocriptine could decrease GH levels in many acromegalic 
patients, although not in all. A further major improvement 
in treatment was the introduction of somatostatin analogs. 
The development of GH receptor antagonists is the latest 
in this line.
Dopamine agonists
Bromocriptine, a dopamine agonist, effectively reduces 
GH secretion in only a minority of GH-secreting adenoma 
(Roelfsema et al 1979; Jaffe and Barkan 1992). Cabergoline, 
a new more potent dopamine agonist with prolonged dura-
tion of action, normalized GH in 35% and IGF-I in 44% of 
46 patients with a purely GH-secreting adenoma in a dose of 
1–1.75 mg/week (Abs et al 1998), but this result has not 
been conﬁ  rmed by others. The efﬁ  cacy was somewhat larger 
in patients co-secreting prolactin. Quinagolide, another 
dopamine agonist, normalized IGF-I in 28% of the patients 
(Freda 2003). Therefore it is not surprising that the addition 
of the dopamine agonist cabergoline to chronic somatostatin 
analog treatment in patients who fail to normalize GH secre-
tion under monotherapy is still able to decrease serum IGF-I 
concentrations into the normal range in 30%–40% of patients, 
irrespective of the prolactin concentration (Cozzi et al 2004). 
Side-effects of cabergoline are rare.
Somatostatin analogs
Somatostatin analog treatment has been the most important 
medical therapy for more than a decade. Compared with 
dopamine agonists this class of drugs is much more efﬁ  -
cient in suppressing GH in acromegaly. The currently used 
analogs, octreotide and lanreotide inhibit GH secretion via 
the somatostatin receptor subtypes 2 and 5 (Hoﬂ  and and 
Lamberts 2003). The plasma half-life is about 20 times 
longer than that of native somatostatin. Although the most 
important effect of somatostatin analogs is the inhibition of 
tumor-derived GH and the subsequent fall in circulating liver-
derived IGF-I, part of the peripheral effects are caused by a 
direct inhibition of IGF-I gene transcription via activation 
after binding to the somatostatin receptor (Serri et al 1992; 
Le Roith et al 2001; Murray et al 2004). The magnitude of 
this latter effect in the various organs is not precisely known. 
The introduction of long-acting repeatable (LAR) forms using 
monthly intramuscularly injectable microspheres of octreotide 
(octreotide-LAR, Sandostatin® LAR®, Novartis Pharmaceuti-
cal, Basel, Switzerland), the 1- to 2-weekly injections with 
lanreotide prolonged release (Somatuline® PR, Ipsen SA, 
Paris, France), and the more recent subcutaneously monthly 
injection formula lanreotide Autogel® (Somatuline® Autogel®, 
Ipsen SA, Paris, France ) has improved further the treatment 
results and facilitated the use of these agents (Freda 2003) 
Several multicenter studies have shown that disease activity 
is controlled in 40%–60% of the patients (Lancranjan et al 
1999; Cozzi et al 2003; Cozzi et al 2006). Other somatostatin 
analogs currently investigated in Phase 2 and 3 studies were 
recently reviewed (Roelfsema et al 2005).
Tumor volume reduction of GH adenoma with a 
weighted mean of 19.4% has been reported to occur in 
62% of acromegalic patients during primary therapy with 
somatostatin analogs (Melmed et al 2005). Medical pretreat-
ment before surgery of especially macroadenoma, however, 
does not clearly improve outcome (Biermasz et al 1999; International Journal of Nanomedicine 2006:1(4) 389
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Ben Shlomo and Melmed 2003). Clinically important is the 
observation that the decrease of GH below 2.2 μg/L during an 
intravenous or subcutaneous test with octreotide predicts the 
long-term GH suppression with octreotide LAR to safe levels, 
thus avoiding non-successful treatment in some patients, 
who will be better off with pegvisomant or combined treat-
ment (see below) (Biermasz et al 2005; Gilbert et al 2005; 
Karavitaki et al 2005).
GH antagonists
Above we have outlined the various therapeutical approaches 
to cure or to control excessive GH secretion. Rather than 
diminishing or normalizing GH secretion at the pituitary 
level, it is also possible to neutralize or diminish the GH 
signal at the peripheral cellular level. Theoretically, this could 
be accomplished by the construction of GH receptor antago-
nists and by RNA antisense techniques, thus preventing the 
synthesis of the GH receptor. Indeed, the recently developed 
antisense oligonucleotide, ATL 227446, effectively inhibited 
hepatic GH receptor expression and IGF-I production and 
decreased body weight gain in mice (Tachas et al 2006). 
Below we shall review the molecular structure of GH and 
its receptor and physiology which all are keystones for the 
development of GH receptor antagonists.
GH and GH receptor structure
GH is synthesized and secreted by the somatotroph cells of 
the anterior pituitary gland. The GH gene consists of 5 exons 
and 4 introns encoding a 217-amino acid precursor protein. 
By proteolysis the amino-terminal signal peptide is removed, 
yielding the mature single chain 191-amino acids polypep-
tide, with a molecular mass of 22 kDa. The 3-dimensional 
structure of human (h) GH and of GH from other mammalian 
species was established by X-ray crystallography (Ultsch 
et al 1991, 1993; de Vos et al 1992). The protein consists 
of four α-helices, with 20–30 residues bound together by 
stretches of non-helical chains which are packed together in 
an antiparallel bundle (Ultsch et al 1994).
The GH receptor belongs to the cytokine-hemopoietine 
receptor superfamily (Bazan 1990). This transmembrane 
protein contains 620 amino acids. The receptor lacks intrinsic 
kinase activity, but GH binding to its extracellular domain 
induces the recruitment and activation of the tyrosine kinase, 
Janus kinase 2 (JAK2). Subsequently, the activated JAK2 
phosphorylates the receptor and STATs (signal transducer 
and activator of transcription), and dimers of the latter are 
translocated to the nucleus to promote gene transcription 
(Carter-Su and Smit 1998).
X-ray crystallography studies of the GH-GH-receptor 
complex and of GH with the extracellular domain of the 
receptor have demonstrated that each GH molecule is 
bound by two receptor molecules, suggesting dimerization 
of the receptor (Figure 3). A former, well-accepted model 
was that the binding site 1 of the GH molecule binds to the 
ﬁ  rst GH receptor, followed by the binding of site two of the 
same GH molecule to the second GH receptor, thus leading 
to dimerization of the receptor (Fuh et al 1992; Behncken 
and Waters 1999). Recent data, however, suggest that the 
mature unbound glycosylated GH receptor is already pres-
ent as a dimer on the cell surface, and moreover that GH 
receptor precursors in the endoplasmatic reticulum already 
form dimers, indicating that dimerization and binding are 
independent processes (Gent et al 2003). Binding of GH 
to the extracellular domains of the receptor dimer causes 
a relative shift and rotation of the subunits (Brown et al 
2005). The conformational change in the GH receptor-dimer 
results in the recruitment and cross-activation of two JAK2 
tyrosine kinase molecules, leading to the activation of the 
receptor and this step is followed by a cascade of intracellular 
phosphorylation and further activations of other pathways, 
including the important STAT-5 pathway, but also those 
of the MAPK, IRS, and/or PKC pathways and followed by 
gene transcription (Pelekanos and Waters 2006). Mutations 
of the extracellular domain of the receptor prevent GH bind-
ing and lead to the so called Laron syndrome, characterized 
by severely stunted growth, GH insensitivity, and increased 
serum GH concentration (Laron et al 1966). Later it was 
Binding site 2
Binding site 1
Figure 3 Crystal structure of growth hormone complexed to the extracellular 
domains of its receptor dimer. The binding sites are indicated by arrows (crystal 
structure determined by de Vos et al 1992, Protein Database code 3HHR, 
downloaded graph modiﬁ  ed in Chimera UCSF).International Journal of Nanomedicine 2006:1(4) 390
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demonstrated that patients with this syndrome had low IGF-I 
and IGFBP3 concentrations. More than 40 different muta-
tions in the human have been described, but mutations of 
the intracellular domain, preventing activation but not GH 
binding, are rare (Rosenbloom 2000).
The number of GH receptors on the cell surface is a 
strictly regulated process, and an important physiological 
determinant of the sensitivity to GH. The GH receptor is 
synthesized and degraded continuously with a half-life of less 
than 60 minutes. The number of receptors at the cell surface 
is mainly regulated by the ubiquitin system (Alves dos Santos 
et al 2001; van Kerkhof et al 2002). An example of receptor 
down-regulation is starvation, which leads to high GH and 
low IGF-I serum concentrations and is caused by increased 
GH receptor degradation (Strous et al 2004).
Growth hormone antagonists
In the search for GH molecules with increased biological 
activity the group of Kopchick substituted amino acids in the 
third α-helix of GH. This site was considered as essential for 
the biological activity of GH (Chen et al 1990).
They generated an altered bovine bGH in which 
glutamate-117 was changed into leucine, glycine-119 into 
arginine, and alanine-122 into aspartate and thus generated an 
idealized amphiphilic α-helix. Surprisingly, transgenic mice 
that expressed the mutated hormone were smaller than the 
wild type littermates. Nevertheless, the altered GH had the 
same binding afﬁ  nity to mouse liver membrane preparations 
as the wild type bGH, indicating that binding and function 
could be dissociated and that the mutated hormone acted 
as an antagonist. Interestingly, the same group of scientists 
found that substitution of glycine for glutamate at position 
126 of bGH increased growth 1.6-fold in transgenic mice 
(Chen et al 1991).
Substitution of glycine at position 120 of the third α-helix 
of human (h) GH with arginine (G120R) or with leucine 
(G120K) decreased growth and serum IGF-I concentration, 
but with full binding to the receptor (Chen et al 1994). Origi-
nally, it was thought that the antagonistic effect of G120R 
(or any long amino acid substitution) prevented receptor 
dimerization, because of the mutation at binding site 2. 
Indirect evidence from several studies, however, showed 
that the mutated molecule is bound by the receptor dimer as 
illustrated in Figure 4 (Harding et al 1996; Ross et al 2001). 
The mutated hormone-receptor complex is rapidly internal-
ized to the same extent and rate as the native GH-GHR 
complex (Harding 1996; Maamra et al 1999). In the human 
the GH antagonists are speciﬁ  c for the GH receptor and they 
do not bind to the prolactin receptor, in contrast to hGH itself 
(Gofﬁ  n et al 1999).
The G120K mutation of hGH was further explored for 
the treatment of acromegaly. Unbound GH has a very short 
half-life of only a few minutes and bound GH (to GH-binding 
protein) of 16–18 minutes, so that treating GH excess with 
the native mutated GH is not practical. Therefore, two strate-
gies were used, ﬁ  rst to increase the binding afﬁ  nity of site 1 
and second the pegylation of the molecule by increasing its 
molecular weight in order to increase its half-life in the cir-
culation. The afﬁ  nity of site 1 for GHBP can be increased by 
mutating residues (Lowman and Wells 1993). In B2036, the 
G120K mutation of hGH, 8 other mutations were introduced 
at binding site 1, thereby increasing afﬁ  nity for recombinant 
GHBP by 4–5-fold compared with GH. However, binding 
afﬁ  nity to the cell surface receptor is equivalent between 
B2036 and GH (Ross et al 2001).
Pegylation was developed in the 1970s by Davis 
and colleagues (Davis et al 1978). It is the covalent 
attachment of polyethylene glycol moieties to therapeu-
tic compounds, including proteins, such as interleukins, 
interferon, asparagines, and GH. Pegylation increases the 
size and molecular weight of the compound and alters the 
physicochemical properties, including the conformation, 
spatial hindrance, and electrostatic binding. The physico-
chemical changes lead to decreased systemic clearance 
by different mechanisms, including decrease in renal 
Figure 4 Interaction of GH, B2036, and B2036/PEG (pegvisomant) with the GH 
receptor. A: GH binds to GH binding protein (GHBP). Binding to its cell surface 
receptor through sites 1 and 2 induces a change in conformation of the receptor 
leading to activation and subsequent signaling. B: the site 2 mutation (x) prevents 
the conformational change needed for activation. C: B2036-PEG binds to GHBP 
via site 1, which is protected from pegylation by mutation of lysines. High dose of 
B2036-PEG is required to overcome the steric hindrance by pegylation. Modiﬁ  ed 
after Ross RJ, Leung KC, Maamra M, et al 2001. Binding and functional studies with 
the growth hormone receptor antagonist B2056-PEG (pegvisomant) reveal effects 
of pegylation and evidence that it binds to a receptor dimmer.  J Clin Endocrinol 
Metab, 86:1716–23. Copyright © 2001, with permission from the Endocrine Society.International Journal of Nanomedicine 2006:1(4) 391
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clearance, proteolysis, and macrophage uptake. In addition, 
the pegylated molecule is heavily hydrated, so that the effec-
tive molecular weight is much greater than the apparent 
molecular weight, which is important for the passage of the 
drug across blood–tissue barriers. Furthermore, the pegylated 
moieties and associated hydration water shield the protein 
from immunogenic recognition and increase the resistance 
to proteolytic enzymes (Harris et al 2001).
In earlier studies long-acting hGH was constructed by 
pegylation of recombinant hGH and the biological effects and 
pharmacokinetics studied in intact and hypophysectomized 
rats (Clark et al 1996). Depending on the level of polyethylene 
glycol (PEG) modiﬁ  cation the afﬁ  nity for the receptor was 
decreased and the clearance rate was inversely proportional 
to the effective molecular weight. The efﬁ  cacy for the PEG-
analogs in vitro and in vivo was optimal for hGH conjugated 
with 5 equivalents of PEG5000 and the potency was increased 
by about 10-fold compared with unmodiﬁ  ed hGH.
Based on these ﬁ  ndings and mutational studies of the 
binding site 1 of hGH which increase binding to the receptor, 
the pegylated B2036 molecule contained three alterations: 
(1) the amino acid substitution in the third alpha helix of 
binding site 2 (Glyc120Lys); (2) 4–6 PEG moieties that 
increase the in vivo half-life of the antagonist; and (3) 8 other 
amino acid alterations at site 1 that increase the afﬁ  nity to 
the GHR (see Figures 4 and 5). Nevertheless, this molecule 
has a 4–5-fold reduced binding to GHBP, but a much greater 
reduction of around 20-fold when binding is studied at the 
cell surface receptor and presumably explained by steric 
hindrance (Pradhananga et al 2002). The construction of 
the drug explains the very long half-life, but also the very 
high dose required for effective receptor blockage in clinical 
practice. This compound has been named pegvisomant and 
is marketed for the treatment of acromegaly Pﬁ  zer (Pﬁ  zer 
Inc, New York, USA) as Somavert®.
Pharmacokinetic 
and pharmacodynamic studies 
with pegvisomant
Most of the pharmacokinetic data on pegvisomant were 
published in two abstracts and as attachment on the internet 
site of the European Medicines Agency (http://www.emea.
eu.int/humandocs/Humans/EPar/Somavert/somavert.htm). 
In a double-blind, placebo-controlled, single rising dose 
study the safety, pharmacokinetics, and pharmacodynamics 
of pegvisomant were investigated in 36 healthy male subjects 
(Rodvold et al 1997). The drug was tolerated in doses from 
0.03 up to 1 mg/kg s.c. Maximal serum concentration was 
dose-dependent and reached values of 9600 ng/ml for the 
highest dose. The time of Cmax was also dose-dependent 
ranging from 15±10 hours at the lowest dose (0.03 mg/kg) 
to 60±18.6 hours for 1.0 mg/kg. The β-component of the 
serum half-life of pegvisomant was dose-independent 
and was about 75 hours. Serum IGF-I was suppressed by the 
0.3 and 1.0 mg/kg doses. Comparable results were obtained in 
6 patients with acromegaly (Rodvold and van der Lely 1999). 
The bioavailability after s.c injection was 56.7% (range 
48.6%–64.7%). The distribution volume amounted to 23.3 L 
for s.c. administration and 12.4 L for i.v. injection. Only a 
very small fraction of unchanged pegvisomant is excreted via 
the urine (0.0015 after s.c. administration vs 0.0041 (com-
ment: fractions are dimensionless) after i.v. injection). The 
mean systemic clearance was estimated to be 28 mL/hour 
for s.c. administered pegvisomant in doses of 10–20 mg. 
The clearance increased by 0.6 mL/hour for each kg of body 
weight greater than the average weight of 94 kg.
Thorner’s group investigated endogenous GH and 
pegvisomant concentrations in 36 healthy young male 
adults, within 15% of ideal body weight. The hormones 
were measured with specific assays. Although IGF-I 
decreased in the higher dose groups (1 mg/kg) no increase 
in endogenous GH occurred, suggesting to the authors that 
pegvisomant did not interfere with hypothalamic feedback 
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Figure 5 Schematic representation of pegvisomant and the attached PEG 
polymers. The amino acid substitutions were introduced at positions G120R 
(binding site 2) and at H18D, H21N, R167N, K168A, D171S, K172R, E174S, 
and I179T (binding site 1). The mutated amino acids are hatched. Two disulﬁ  de 
bridges between amino acids 53 and 165 and between 182 and 189 are shown by 
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(Thorner et al 1999). In contrast, the group of Veldhuis 
convincingly demonstrated with the aid of intensive venous 
sampling the increase in GH secretion after 1 mg/kg in 
12 healthy volunteers (Veldhuis et al 2001). Speciﬁ  cally, 
they found a linear relation between the decrease in IGF-I 
and the increase in GH burst amplitude. In patients with acro-
megaly GH concentrations increase while on GH receptor 
blockade, similar to that demonstrated in healthy subjects. 
However, it is not known whether diminished feedback via 
circulating IGF-I at the pituitary and/or hypothalamic level 
is solely responsible for the increased GH secretion. Direct 
intracerebroventricular administration of the unpegylated 
GH antagonist B2036 in rats leads to increased GH release, 
pointing to the presence of a short feedback loop (Nass et al 
2000). At present it is not well known whether pegvisomant 
can penetrate into the hypothalamus, but it is stated that the 
radio-labeled drug does not cross the blood–brain barrier 
(product information EMEA), thus favoring an indirect 
effect via IGF-I.
Comparable questions may be asked for effects observed 
in organs other than the liver, ie, are eventual changes in 
organ responses the result of diminished liver IGF-I synthesis 
and subsequent decrease in circulating IGF-I or are effects 
also (or mainly) mediated via local blocking of the GH 
receptor? Unfortunately, this issue was never speciﬁ  cally 
addressed, but below we summarize some in vivo and in 
vitro studies in which peripheral effects were investigated. 
In mice, pegvisomant increased, in a dose-dependent way, 
liver mRNA of the GH receptor and the binding protein and 
decreased mRNA of IGF-I, but no corresponding changes 
were found in the kidneys (Van Neck et al 2000). In another 
study, high protein feeding in mice caused renal hypertrophy 
associated with increased circulating IGF-I (Van Neck et al 
2002). However, pegvisomant treatment did not prevent renal 
hypertrophy and the authors concluded that this effect is 
GH-independent, a conclusion which is certainly acceptable 
only if pegvisomant was blocking effectively the renal GH 
receptors. Indeed, both studies did not provide any evidence 
for blocking of the renal GHR.
In another study, human meningiomas were xeno-
grafted in nude mice. Tumors in pegvisomant-treated 
mice showed a mean volume decrease of 31.8% while the 
placebo- treated group had a 23.2% increase after 8 weeks. 
Serum IGF-I was moderately decreased in the pegvisomant 
group (257 vs 319 μg/L), but IGF-I was not detectable 
in the tumors (McCutcheon et al 2001), suggesting that 
the drug acted directly on these tumors. Pegvisomant 
administration to the rhesus monkey (slowly) decreased 
bone turnover, and the inhibitory effect could be abolished 
quickly by the simultaneous treatment with IGF-I (Wilson 
2000). However, this study does not allow a distinction 
between endocrine and auto- or paracrine mechanisms 
of IGF-I.
Nevertheless, pegvisomant had a clear direct cellular 
effect in vitro in the following two studies. Growth hormone, 
both the 20 kDa and the 22 kDa isoforms, amplify GHR and 
GHBP gene transcription in human mesangial cells in vitro 
and this effect was blocked speciﬁ  cally by pegvisomant 
(Meinhardt et al 2003). That pegvisomant could block the 
GH receptor in vitro was also demonstrated in an elegant 
Table 1 Effect of pegvisomant treatment on IGF-I normalization in acromegaly
Study No of pts Dose Duration % normal IGF-I Remarks
Trainer et al (2000) 110 placebo
10 mg qd
15 mg qd
20 mg qd
12 weeks 10
38
75
82
99 patients had pituitary
surgery and/or irradiation
van der Lely et al (2001) 160 individualized
(10–40 mg qd)
Up to 
18 months
(n = 39)
97 GH increased by 100%.
decrease of fasting
glucose and insulin
dose ﬁ  nding study.
Jehle et al (2005) 10 10–40 mg qd,
q2/3 or biw
7–24 months 100 previous surgery in all
Jørgensen et al (2005) 11 10 mg or 15 mg
combined with
octreotide
6–12 weeks 90
Feenstra et al (2005) 26 40–80 mg/week
combined with
octreotide LAR
or Lanreotide Autogel
42 weeks 95% mild increase of liver 
transaminases in 38%
Abbreviations: IGF-1, insulin-like growth factor-I.International Journal of Nanomedicine 2006:1(4) 393
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series of experiments on phosphorylation and transcriptional 
effects of autocrine hGH in human mammary carcinoma cell 
lines (Kaulsay et al 2001).
Clinical studies with pegvisomant
The ﬁ  rst study reporting efﬁ  cacy of the drug was a multicenter, 
double-blind study comprising 112 patients (Table 1). The 
majority of the patients had undergone previous treatment 
by surgery, radiation therapy, or a combination. Because of 
active disease 81 patients were on treatment with somatostatin 
analogs and/or dopamine agonists. Nine patients were treated 
only with medication and 4 patients had never been treated 
before. As expected, GH concentration was rather low after 
withholding the drugs (8.1±10.6 ng/mL). After a loading 
dose of 80mg pegvisomant (or placebo) patients received 
placebo, 10, 15, or 20 mg pegvisomant per day for 6 weeks. 
IGF-I normalized in 0%, 38%, 75%, and 82% of the patients, 
respectively. Soft tissue swelling, perspiration, and fatigue 
all improved in the 15- and 20-mg treated groups. No serious 
side-effects were noted, except for 1 patient who developed 
liver function abnormalities on 2 occasions when exposed 
to the drug. Liver function normalized after withholding the 
drug (Trainer et al 2000). The second large study enrolled 
160 patients who were treated for a mean duration of 425 
days (van der Lely et al 2001). These patients had undergone 
previous treatments: surgery 86%, pituitary irradiation 56%, 
somatostatin analog medication 74%, and dopamine agonists 
48%. Patients received daily s.c. injections, with a starting 
dose of 10mg and increases of 5 mg until a normal IGF-I was 
obtained or the maximal dose of 40 mg/day was reached. 
The total number of dropouts for various reasons was 30 
patients, including 5 patients in whom therapy was withheld 
because of lack of efﬁ  cacy. The entry criterion for the study 
was a 1.3-fold increased IGF-I level, corrected for age after 
discontinuation of GH-suppressive medicines. The mean 
GH concentration at entry was only moderately increased 
to 10.9 μg/L. The mean GH increase after 18 months was 
33.8 μg/L. Normal IGF-I was obtained in 87 of 90 patients 
at 12 months, and of all post-basal blood samples normal 
IGF-I was measured in 91.7%. Fasting insulin concentra-
tion decreased to 12.2 mU/L, but HbA1c values did not 
change. Residual tumor mass did not increase (2.41±0.31 
to 2.37±0.31mL) but in 2 patients the size of the adenoma 
increased, requiring surgery in on patient and radiotherapy in 
Table 2 Effect of pegvisomant treatment on metabolic parameters in acromegaly
Study No of pts Dose Duration Parameter(s) Outcome
Trainer et al (2001) 7 20 mg qd 46 weeks 11-β-hydroxyl steroid  decreased inhibition
Sesmilo et al (2002) 47 placebo
or 10–20 mg qd
12 weeks dehydrogenase CRP, HDL, 
LDL and cholesterol, IL-6, 
homocysteine, total insulin
CRP increased, other parameters 
unchanged
Parkinson et al (2002a) 6 20 mg qd 7 days glucose, insulin, gastrin, CCK, PP no changes.
Parkinson et al (2002b) 20 5-mg increments
from 10 mg qd
till IGF-I
normalization
lipoproteins, insulin IGF-I normal in 100%, increase of 
TC, LDL, apo-B, decrease of insulin, 
insulin resistance; decrease of fasting 
glucose and insulin concentrations
Fairﬁ  eld et al (2002) 27 placebo, 10–20 mg qd 12 weeks bone formation and resorption decrease of bone turnover
Parkinson et al (2003a) 16 10–40 mg qd, 3–11 months leptin increase in total leptin
Drake et al (2003b) 7 cross-over octreotide
to pegvisomant
(10–25 mg qd)
octreotide
17–19 months;
pegvisomant
7–9 months
fasting glucose and insulin, 
HOMA-%S, HOMA-%β, insulin 
sensitivity, body composition
glucose decreased, insulin increased, 
improved insulin secretion and 
sensitivity
Parkinson (2003) 16 10–40 mg qd 3–11 months bone formation, resorption, 
PTH, vitamin D3
normalization of bone turnover, 
PTH increase, 1–25 (OH)2 vitamin 
D3 decrease
Barkan et al (2005) 53 conversion from 
octreotide to 
pegvisomant
10–40 mg qd
28 weeks HbA1c, glucose IGF-I normal in 78%, decrease of 
glucose and HbA1c
Abbreviations: apo-B, apolipoprotein B; CCK, cholecystokinin; CRP, C-reactive protein; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; HOMA, 
homeostasis model assessment; HOMA-%S, estimate for insulin insensitivity; HOMA- %β, estimate of β-cell function; IGF-1, insulin-like growth factor-I; Il-6, interleukin-6; 
LDL, low-density lipoprotein; PP, pancreatic polypeptide; TC, triglycerides; PTH, parathyroid hormone.International Journal of Nanomedicine 2006:1(4) 394
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the other. Two patients showed a 10-fold reversible increase 
in alanine amino transferase and aspartate amino transferase. 
A drawback of these two studies is that they may be biased 
by patient selection, and therefore the conclusion that the 
drug is excellent might only be applicable for patients who 
had persisting disease activity after surgery and/or pituitary 
radiotherapy.
Other GH-dependent parameters were generally studied in 
small groups of patients, being part of larger studies (Table 2). 
Trainer and colleagues found during pegvisomant treatment 
in 7 patients a shift from cortisone to cortisol metabolism, 
indicating the reversal of the well-known inhibition of GH 
on 11-β-hydroxysteroid dehydrogenase (Trainer et al 2001). 
In a case-controlled study of cardiovascular risk factors 
in acromegaly, the normalization of the very low serum 
C-reactive protein concentration was described, but other 
risk factors including cholesterol, interleukin-6, homocystein, 
and insulin concentrations remained unchanged during the 
3-month treatment period. The clinical signiﬁ  cance of this 
ﬁ  nding is presently unknown (Sesmilo et al 2002). In a study 
by Parkinson in 16 patients increased leptin levels were 
found during pegvisomant treatment (Parkinson et al 2003a). 
Several studies showed improved glucose tolerance during 
treatment with pegvisomant (Rose and Clemmons 2002). 
Three other studies with more patients showed insulin sensi-
tivity and glucose tolerance in patients converted from depot 
octreotide to pegvisomant (Parkinson et al 2002; Drake et al 
2003; Barkan et al 2005). Increased bone turnover is a well-
known feature of untreated acromegaly. In two studies the 
increased serum markers for bone formation and bone resorp-
tion decreased in parallel with normalization of IGF-I during 
pegvisomant therapy, while in one study PTH increased 
with concomitant decrease of 1, 25-dihydroxy-vitamin D3 
(Fairﬁ  eld et al 2002; Parkinson 2003b) . These results on bone 
metabolism, but also on insulin and leptin, are not unexpected 
since they are under GH-IGF-I control. The unsolved ques-
tion, however, is whether these effects are caused exclusively 
by diminished liver-derived IGF-I or whether the eventually 
locally decreased GH signal and paracrine effect of IGF-I 
contributes to peripheral (non-liver-associated) effects.
Three other studies have explored either different dosing 
interval of pegvisomant or combining pegvisomant with soma-
tostatin analogs on efﬁ  cacy. In an elegant and well-designed 
study in 11 patients by Jørgensen and co-workers, treatment 
with low-dose pegvisomant (15 mg/day) and octreotide–LAR 
was clearly superior in suppressing IGF-I. Notwithstanding 
the well-known suppressive effect of somatostatin analogs on 
insulin secretion the combined treatment had similar effects 
on glucose and insulin secretion as pegvisomant alone. An 
interesting, unexplained observation in this study was the 
20% increased circulating pegvisomant concentrations dur-
ing combined treatment with octreotide (Jørgensen et al 
2005). In the study by Jehle and colleagues, comprising only 
10 patients, alternate day pegvisomant therapy was equally 
effective as daily injections in 5 patients (Jehle et al 2005). 
Finally, in a single-center, 42-week, open-label prospective 
dose ﬁ  nding study, 26 acromegalic patients (of whom 14 
were previously untreated) received monthly injections with 
30 mg Sandostatin LAR or 120 mg lanreotide Autogel and 
increasing weekly doses of pegvisomant. Under somatostatin 
analog mono-treatment all patients had elevated IGF-I levels, 
but after combined treatment with a median weekly dose of 
60 mg pegvisomant 95% of the patients had normalized their 
IGF-I levels. Mild increases in liver enzymes were found in 
38% of the patients during combined treatment. These stud-
ies together suggest that a longer dosing interval than daily 
injections is feasible in patients and that a relatively low dose 
of pegvisomant combined with slow-release somatostatin 
analogs is able to suppress effectively the GH-IGF-I axis, even 
in untreated patients (Feenstra et al 2005). The results of the 
last two studies fully concur with the available data on plasma 
half-life and plasma residence time of the drug in man.
Clinical practice
Pegvisomant (Pﬁ  zer Inc, New York, USA) is supplied as a 
lyophilized powder and the vial must be reconstituted with 
1 mL of the diluent (sterile water, USP). After reconstitu-
tion each vial contains 10, 15, or 20 mg of the pegvisomant 
protein in 1 mL of solution. The company advises a subcu-
taneous loading dose of 40 mg under the supervision of a 
physician and then daily s.c. injections with 10 mg or more 
(dose increases of 5 mg in 6-weekly intervals) until a normal 
age-adjusted IGF-I level is reached. The maximal daily dose 
should not exceed 30 mg. However, the pegvisomant dose 
may be tailored and less frequent injections may be sufﬁ  cient 
in selected patients, as reviewed above. Less frequent dos-
ing seems logical because of the known half-life, although 
weekly dosing might become critical at lower doses in many 
patients, as was observed in unpublished trials. Although 
not recommended by the Pﬁ  zer, patients might beneﬁ  t from 
the combination of a slow-release somatostatin analog and 
weekly pegvisomant injection (Feenstra et al 2005).
The most important side-effects of pegvisomant are 
disturbance of liver function tests and, in rare cases, growth 
of the pituitary adenoma. Therefore, regular control of liver 
function tests should be performed (Biering et al 2006). International Journal of Nanomedicine 2006:1(4) 395
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In addition, before starting treatment with pegvisomant, MRI 
studies of the adenoma should be carried out and repeated at 
yearly intervals. In selected cases, especially in patients with 
suprasellar extension of the adenoma, tests of the visual acu-
ity and visual ﬁ  elds should be performed on a regular basis. 
Most other side-effects are mild and generally restricted to 
local irritation at the injection site. The dose of hypoglyce-
mic drugs in diabetic patients might be reduced, because 
of improved insulin sensitivity, and careful monitoring of 
glucose levels is advised.
Neutralizing, low titer GH antibodies are present in 
about 17% of patients, but no tachyphylaxis has occurred. 
Pituitary-derived GH concentration rises during pegvisomant 
treatment until a stable IGF-I level is obtained. The GH 
increase is dose-dependent, but can be demonstrated only 
with specially adapted assays.
Unsolved questions
1.    All studies with pegvisomant are short-term studies and 
the long-term efﬁ  cacy is not known. Clariﬁ  cation is 
needed whether in man the drug is mainly acting via its 
IGF-I-suppressive effect on the liver or whether the GH 
receptor is blocked effectively in all organs. Even if the 
latter is true then the brain still escapes from this effect, 
since pegvisomant does not cross the blood–brain bar-
rier and its long-term consequence on brain function is 
unknown.
2.    Long-term studies are required to evaluate the safety on 
pituitary adenoma size in patients primarily treated with 
pegvisomant only, since these tumors have a slow growth 
rate.
3.    No studies have compared the efﬁ  cacy of slow-release 
somatostatin analogs with that of pegvisomant. Such a 
(long-term) study is badly needed and should primarily 
focus on normalization of IGF-I, but should also 
document parameters which are more dependent on local 
GH-IGF-I effects and less on circulating IGF-I.
4.   No study with primary medical treatment has investigated 
the inﬂ  uence on the quality of life and on mortality in 
acromegaly, in contrast to what is known presently from 
surgical patient series.
Place of pegvisomant 
in the treatment of acromegaly
For the initial treatment of acromegaly, both trans-
sphenoidal surgery and treatment with somatostatin analogs 
can be attempted. The choice between the two modalities 
depends on several factors, including the available surgical 
experience of the center, the preference of the patient 
and comorbidity, resulting in contraindications for either 
treatment option. In addition, the size of the adenoma, the 
presence of optic chiasm compression, and the level of GH 
should be taken into account. Octreotide is able to achieve 
disease control, especially in patients with documented 
good sensitivity for octreotide and relatively low GH lev-
els. Primary radiosurgery could be applied in experienced 
centers in patients harboring tumors invading the cavernous 
sinus, not related to optic structures, and that have a low a 
priori chance for surgical cure. Pegvisomant seems to be 
an effective drug as supplement to long-acting slow-release 
somatostatin analogs (ie, Sandostatin LAR or lanreotide 
Autogel), when IGF-I levels remain elevated. Primary 
treatment with pegvisomant alone should be done at present 
only as part of long-term studies which are necessary to 
deﬁ  ne its precise role. In case of equal potency the choice 
should be dictated by the costs of life-long GH-suppressive 
therapy.
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